大鼠血管内皮细胞siRNA转染条件的优化

目的:旨在优化siRNA转染大鼠血管内皮细胞的转染条件.方法:将0.75μL和1.5μL的脂质体LipofectamineTM3000分别与20、40、60、80nmol带荧光标记的FAMsiRNA组合,转染6、12、18、24h后,用荧光显微镜计数阳性细胞率、MTT法检测各浓度条件下内皮细胞的存活率,筛选最优转染条件.结果:(1)转染12h后,用荧光显微镜检测20、40、60、80nmol各组,均可观察到绿色荧光(2)siRNA浓度为60nmol/L,脂质体为1.5μL的组合转染效率最高,继续增加siRNA的浓度,转染效率提高不明显.(3)转染时间超过24h,各组细胞荧光减弱,细胞死亡率显著增加.结论:结果表明,以1.5μL LipofectamineTM3000与60nmol/L的siRNA浓度组成转染混合物转染12h可以实现对大鼠血管内皮细胞高效转染并保持较高的细胞活性.     

几种内源性小RNA的比较

RNA干涉是近年来的研究热点,广泛参与生物发育、细胞分化、细胞凋亡等多种生物学过程。本文综述了近年来对转录后靶基因调控的几种小RNA：siRNA、microRNA、piRNA和endo-siRNA,从特点、生物发生过程和生物学功能方面进行了综述性地比较,以期为进一步深入研究提供参考。     

RNAi与siRNA在医学中应用的新进展

RNAi（RNA interference,RNAi）是序列特异的双链RNA（dsRNA）使细胞内同源性mRNA降解,产生特异的基因沉默的过程．RNAi最早是由Fire在线虫实验中发现并提出的．随后,在其他动物包括哺乳动物中也发现了RNAi．RNAi技术是一种发展很快并有应用前景的基因控制技术,目前已广泛地应用于多学科的研究,尤以医学领域的研究最为突出,它不仅可用于基础研究,而且为病毒感染性疾病和肿瘤的防治开辟了更为广阔的前景．     

Delayed resistance to Cucumber mosaic virus mediated by 3’UTR-derived hairpin RNA

RNA silencing has been shown to function in the plant antivirus defense response, leading to viral RNA degradation induced by vsiRNA-containing RISC cleavage activity. Cucumber mosaic virus （CMV） 3′UTR sequences share a high conservation of nucleotide sequence and secondary structures that are important for CMV replication. Here, in an attempt to simultaneously target the multiple genomic and subgenomic RNAs of CMV for degradation, CMV 3′UTR were used to design hairpin RNA （hpRNA） to transform tobacco （Xanthi. nc） so as to constitutively produce viral siRNAs. Most of the transgenic plants expressing CMV Q strain （Q-CMV, subgroup Ⅱ strain） RNA3 3′UTR-derived hpRNA showed delayed resistance to Q-CMV infection and exhibited recovery phenotypes. Compared with Q-CMV-inoculated leaves, the upper leaves showed weak or no disease symptoms and a reduced accumulation level of viral RNAs. Together with transient assays, our results indicate that the 3′UTR-derived siRNAs were biologically active in targeting viral RNA for degradation. Recovery resistance in transgenic plants was also observed against subgroup IB strain SD-CMV infection, indicating a broad-spectrum anti-CMV effect of the 3′UTR-based antiviral silencing. Northern blot assays indicated that there was no strong correlation between the degree of resistance and the accumulation level of 3′UTR-derived siRNAs, suggesting that to target a highly structured RNA, such as the CMV 3′UTR, the quantity of siRNAs may not be the only determinant of silencing efficiency. Target RNA secondary structures may also affect target accessibility, siRNA-containing RISC-target recognition and the consequent antiviral effect.     

Knockdown of <Emphasis Type="Italic">MRP4</Emphasis> by lentivirus-mediated siRNA improves sensitivity to adriamycin in adriamycin-resistant acute myeloid leukemia cells

Chemotherapy remains the standard treatment for acute myeloid leukemia;however,the emergence of drug resistance is a major hurdle in the successful treatment of leukemia.The expression of multidrug resistance-associated protein 4(MRP4)induces re- sistance in the adriamycin-resistant acute myeloid leukemia cell line,K562/ADR.The aim of this study was to investigate whether knockdown of MRP4 by lentivirus-mediated siRNA could improve the sensitivity of K562/ADR cells to adriamycin.Five lenti- virus-mediated short hairpin RNAs(lv-shRNAs-MRP4)were designed to trigger the gene silencing RNA interference(RNAi) pathway.The efficiency of lentivirus-mediated siRNA infection into K562/ADR cells was determined using fluorescence mi- croscopy to observe lentivirus-mediated GFP expression.MRP4 expression in infected K562/ADR cells was evaluated by real- time PCR and Western blot analysis.The MTS assay was used to measure cell viability and flow cytometry was used to measure apoptosis.The transfection efficiency of K562/ADR cells was over 80 percent.The gene silencing efficacy of lv-shRNA1-MRP4 was superior to the other constructs.Infection of K562/ADR cells with lv-shRNA1-MRP4 led to strong inhibition of MRP4 mRNA and protein expression.Combined treatment with lv-shRNA1-MRP4 and adriamycin decreased cell growth and increased apoptosis compared to treatment with lv-shRNA1-MRP4 or adriamycin alone.These data indicate that in K562/ADR cells MRP4 is involved in drug resistance mechanisms and that lentivirus-mediated knockdown of MRP4 may enhance sensitivity to adriamycin.     

小分子RNA家族中的新成员--microRNA

近来,人们在多种生物中发现了一类新的小分子RNA——microRNA(miRNA)．miRNA是20～24nt的单链RNA,在进化上具有高度的保守性,它通过与靶mRNA不完全互补配对,抑制蛋白翻译,调节内源基因表达,在基因调控中扮演了重要的角色．miRNA和siRNA(small interferenceRNA)在生成机制、作用途径等方面关系密切,它们既有区别又相互联系．小分子RNA的研究将是今后分子生物学的研究热点之一．     

RNA干扰技术及其应用

RNA干扰(RNA in terference,RNA i)技术是抑制和逆转基因表达的新型生物学研究工具.论述了RNA i的作用机制及其在基因组学、基因治疗、药物探查等方面的应用情况.d sRNA在酶切作用下产生siRNA,后者与RNA诱导沉默复合物R ISC结合,共同降解靶mRNA,从而达到阻断特异基因表达的目的.该技术已对基因功能、基因治疗和药物筛选等方面的体外实验产生了深刻的影响,但由于存在一些尚未解决的问题,这项技术尚未进行大规模临床应用.     

用siRNA抑制胃癌细胞AGS中COX-2表达及对AKT磷酸化的抑制

构建了可在真核细胞中表达针对COX-2基因的siRNA表达载体，并用胃腺癌细胞系AGS建立了COX-2 siRNA的稳定转染细胞系。用Western-Blot检测稳定转染细胞系中COX-2的表达以及AKT的磷酸化水平。结果表明稳定转染C0X-2 siRNA的细胞中COX-2的表达较转染空载体的细胞明显降低，且发现COX-2表达的降低可抑制AKT—Ser^473和Thr-^308的磷酸化水平。为进-步探索抑制COX-2对胃癌细胞生物学特性的影响，及其在肿瘤治疗中的作用奠定了基础。     

国际RNA的基础和应用研究近况

RNA分子将有望在不久的将来成为制服病毒和癌症的强大工具.20世纪80年代核酶(ribozyme)的发现,使RNA的研究进入了一个崭新的时代,利用RNA分子作为防病治病的工具已成为可能.最近,siRNA的发现,使RNA的研究推向顶峰.文中对国际上RNA研究的现状进行了综述.     

在Hep G2细胞中利用siRNA沉默GFP基因的实验探讨

目的:通过探讨小分子双链RNA(siRNA)通过RNA干扰(RNAi)机制沉默肝癌细胞株Hep G2荧光素报告基因GFP的各项生物学指标,为进一步实验和临床研究提供依据.方法:通过体外实验,对siRNA和siRNA脂质体的稳定性和细胞毒性进行评估;通过荧光标记技术,研究不同时间siRNA脂质体的转染效率;通过荧光显微镜下观察转染细胞和RT-PCR检测靶基因mRNA表达,确定不同种类、形式、剂量的siRNA对靶基因的沉默效能.结果:在空白培养液中,siRNA和siRNA脂质体可稳定至4h,在5%血清中2～4h后明显降解;100nM的siRNA和siRNA脂质体无明显细胞毒性;siRNA脂质体转染细胞株的效率随时间不同而不同,4h可达90%;非特异性siRNA/脂质体无沉默靶基因表达作用,特异性siRNA/脂质体对靶基因的沉默作用在一定范围内随剂量升高(20nM、50nM、100nM)而升高.结论:siRNA的稳定性可满足实验需要,且无明显细胞毒性,特异性siRNA转染肝癌细胞株能有效抑制靶基因表达,用脂质体转染可提高转染效率.siRNA通过RNAi机制沉默靶基因表达,为肿瘤的治疗和基础研究提供了新的工具和思路.